Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1989 Feb;75(2):184–189.

Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection.

K Ljunggren 1, A Karlson 1, E M Fenyö 1, M Jondal 1
PMCID: PMC1542110  PMID: 2649286

Abstract

Peripheral blood mononuclear cells, PBMC, from 64 HIV-1-infected patients were tested for natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) functions against HIV-1-infected U937 clone 2 cells. The ADCC function was tested both with serum and effector cells from the same patient, with an HIV-1 antibody positive serum and with rabbit IgG antibodies against beta 2-microglobulin expressed on the virus-infected target cells. NK and ADCC functions were often found to be suppressed in HIV-1-infected individuals regardless of the severity of HIV-1 infection. The fact that impaired effector cell functions could be detected even in asymptomatic carriers, suggests that profound changes in cellular immunity may be present at an early stage of HIV-1 infection.

Full text

PDF
184

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asjö B., Ivhed I., Gidlund M., Fuerstenberg S., Fenyö E. M., Nilsson K., Wigzell H. Susceptibility to infection by the human immunodeficiency virus (HIV) correlates with T4 expression in a parental monocytoid cell line and its subclones. Virology. 1987 Apr;157(2):359–365. doi: 10.1016/0042-6822(87)90278-9. [DOI] [PubMed] [Google Scholar]
  2. Bonavida B., Katz J., Gottlieb M. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2. J Immunol. 1986 Aug 15;137(4):1157–1163. [PubMed] [Google Scholar]
  3. Chesebro B., Wehrly K. Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity. J Exp Med. 1976 Jan 1;143(1):85–99. doi: 10.1084/jem.143.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dalgleish A. G., Beverley P. C., Clapham P. R., Crawford D. H., Greaves M. F., Weiss R. A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984 Dec 20;312(5996):763–767. doi: 10.1038/312763a0. [DOI] [PubMed] [Google Scholar]
  5. Fontana L., Sirianni M. C., de Sanctis G., Carbonari M., Ensoli B., Aiuti F. Deficiency of natural killer activity, but not of natural killer binding, in patients with lymphoadenopathy syndrome positive for antibodies to HTLV-III. Immunobiology. 1986 Jul;171(4-5):425–435. doi: 10.1016/S0171-2985(86)80074-2. [DOI] [PubMed] [Google Scholar]
  6. Gupta S. Abnormality of Leu 2+7+ cells in acquired immune deficiency syndrome (AIDS), AIDS-related complex, and asymptomatic homosexuals. J Clin Immunol. 1986 Nov;6(6):502–509. doi: 10.1007/BF00915256. [DOI] [PubMed] [Google Scholar]
  7. Katz J. D., Mitsuyasu R., Gottlieb M. S., Lebow L. T., Bonavida B. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity. J Immunol. 1987 Jul 1;139(1):55–60. [PubMed] [Google Scholar]
  8. Klatzmann D., Barré-Sinoussi F., Nugeyre M. T., Danquet C., Vilmer E., Griscelli C., Brun-Veziret F., Rouzioux C., Gluckman J. C., Chermann J. C. Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science. 1984 Jul 6;225(4657):59–63. doi: 10.1126/science.6328660. [DOI] [PubMed] [Google Scholar]
  9. Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., Gluckman J. C., Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 1984 Dec 20;312(5996):767–768. doi: 10.1038/312767a0. [DOI] [PubMed] [Google Scholar]
  10. Lane H. C., Fauci A. S. Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol. 1985;3:477–500. doi: 10.1146/annurev.iy.03.040185.002401. [DOI] [PubMed] [Google Scholar]
  11. Lipinski M., Tursz T., Kreis H., Finale Y., Amiel J. L. Dissociation of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity in kidney allograft recipients receiving high-dose immunosuppressive therapy. Transplantation. 1980 Mar;29(3):214–218. doi: 10.1097/00007890-198003000-00010. [DOI] [PubMed] [Google Scholar]
  12. Lipinski M., Virelizier J. L., Tursz T., Griscelli C. Natural killer and killer cell activities in patients with primary immunodeficiencies or defects in immune interferon production. Eur J Immunol. 1980 Apr;10(4):246–249. doi: 10.1002/eji.1830100405. [DOI] [PubMed] [Google Scholar]
  13. Ljunggren K., Böttiger B., Biberfeld G., Karlson A., Fenyö E. M., Jondal M. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol. 1987 Oct 1;139(7):2263–2267. [PubMed] [Google Scholar]
  14. Ljunggren K., Chiodi F., Biberfeld G., Norrby E., Jondal M., Fenyö E. M. Lack of cross-reaction in antibody-dependent cellular cytotoxicity between human immunodeficiency virus (HIV) and HIV-related West African strains. J Immunol. 1988 Jan 15;140(2):602–605. [PubMed] [Google Scholar]
  15. Ljunggren K., Fenyö E. M., Biberfeld G., Jondal M. Detection of antibodies which mediate human immunodeficiency virus-specific cellular cytotoxicity (ADCC) in vitro. J Immunol Methods. 1987 Nov 23;104(1-2):7–14. doi: 10.1016/0022-1759(87)90481-9. [DOI] [PubMed] [Google Scholar]
  16. Lyerly H. K., Matthews T. J., Langlois A. J., Bolognesi D. P., Weinhold K. J. Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A. 1987 Jul;84(13):4601–4605. doi: 10.1073/pnas.84.13.4601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Merrill J. E., Ullberg M., Jondal M. Influence of IgG and IgM receptor triggering on human natural killer cell cytotoxicity measured on the level of the single effector cell. Eur J Immunol. 1981 Jul;11(7):536–541. doi: 10.1002/eji.1830110703. [DOI] [PubMed] [Google Scholar]
  18. Ojo-Amaize E. A., Nishanian P., Keith D. E., Jr, Houghton R. L., Heitjan D. F., Fahey J. L., Giorgi J. V. Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells. J Immunol. 1987 Oct 1;139(7):2458–2463. [PubMed] [Google Scholar]
  19. Pearson G. R., Johansson B., Klein G. Antibody-dependent cellular cytotoxicity against Epstein-Barr virus-associated antigens in African patients with nasopharyngeal carcinoma. Int J Cancer. 1978 Aug 15;22(2):120–125. doi: 10.1002/ijc.2910220203. [DOI] [PubMed] [Google Scholar]
  20. Pearson G. R., Qualtiere L. F., Klein G., Norin T., Bal I. S. Epstein-Barr virus-specific antibody-dependent cellular cytotoxicity in patients with Burkitt's lymphoma. Int J Cancer. 1979 Oct 15;24(4):402–406. doi: 10.1002/ijc.2910240405. [DOI] [PubMed] [Google Scholar]
  21. Plaeger-Marshall S., Spina C. A., Giorgi J. V., Mitsuyasu R., Wolfe P., Gottlieb M., Beall G. Alterations in cytotoxic and phenotypic subsets of natural killer cells in acquired immune deficiency syndrome (AIDS). J Clin Immunol. 1987 Jan;7(1):16–23. doi: 10.1007/BF00915420. [DOI] [PubMed] [Google Scholar]
  22. Poli G., Introna M., Zanaboni F., Peri G., Carbonari M., Aiuti F., Lazzarin A., Moroni M., Mantovani A. Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. Clin Exp Immunol. 1985 Oct;62(1):128–135. [PMC free article] [PubMed] [Google Scholar]
  23. Rook A. H., Lane H. C., Folks T., McCoy S., Alter H., Fauci A. S. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol. 1987 Feb 15;138(4):1064–1067. [PubMed] [Google Scholar]
  24. Rook A. H., Masur H., Lane H. C., Frederick W., Kasahara T., Macher A. M., Djeu J. Y., Manischewitz J. F., Jackson L., Fauci A. S. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest. 1983 Jul;72(1):398–403. doi: 10.1172/JCI110981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ruscetti F. W., Mikovits J. A., Kalyanaraman V. S., Overton R., Stevenson H., Stromberg K., Herberman R. B., Farrar W. L., Ortaldo J. R. Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells. J Immunol. 1986 May 15;136(10):3619–3624. [PubMed] [Google Scholar]
  26. Shore S. L., Cromeans T. L., Romano T. J. Immune destruction of virus-infected cells early in the infectious cycle. Nature. 1976 Aug 19;262(5570):695–696. doi: 10.1038/262695a0. [DOI] [PubMed] [Google Scholar]
  27. Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 1976 May 15;17(5):565–577. doi: 10.1002/ijc.2910170504. [DOI] [PubMed] [Google Scholar]
  28. Weinhold K. J., Bolognesi D. P., Matthews T. J. Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors. J Natl Cancer Inst. 1985 Oct;75(4):717–724. [PubMed] [Google Scholar]
  29. de Noronha F., Baggs R., Schäfer W., Bolognesi D. Prevention of oncornavirus-induced sarcomas in cats by treatment with antiviral antibodies. Nature. 1977 May 5;267(5606):54–56. doi: 10.1038/267054a0. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES